362598-70-7

Basic information

• Product Name: 3-benzyloxy-1-[2-(1-methyl-pyrrolidin-2-yl)-ethyl]-1H-pyridin-4-one
• CAS NO: 362598-70-7
• Molecular Weight: 312.412
• Mol File: 362598-70-7.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 3-benzyloxy-1-[2-(1-methyl-pyrrolidin-2-yl)-ethyl]-1H-pyridin-4-one(CAS DataBase Reference)
• NIST Chemistry Reference: 3-benzyloxy-1-[2-(1-methyl-pyrrolidin-2-yl)-ethyl]-1H-pyridin-4-one(362598-70-7)
• EPA Substance Registry System: 3-benzyloxy-1-[2-(1-methyl-pyrrolidin-2-yl)-ethyl]-1H-pyridin-4-one(362598-70-7)

Safety Data

• Hazardous Substances Data: 362598-70-7(Hazardous Substances Data)

Upstream product

• 100-44-7 benzyl chloride 
• 1219-33-6 5-(benzyloxy)-4-oxo-4H-pyran-2-carboxylic acid 
• 15771-06-9 5-benzyloxy-2-hydroxymethyl-4H-pyran-4-one 
• 501-30-4 5-hydroxy-2-(hydroxymethyl)-4H-pyran-4-one 
• 61049-67-0 3-Benzyloxy-4-pyrone 
• 51387-90-7 2-(2-AMINOETHYL)-1-METHYLPYRROLIDINE 

Relevant articles and documents

Synthesis of 4(1H)-pyridinone derivatives and investigation of analgesic and antiinflammatory activities

This paper describes recent result of a research program aimed at the synthesis and pharmacological evaluation of new 4(1H)-pyridinone derivatives belonging to the 1,3-disubstituted series (4-11). These compounds were structurally planned by applying the molecular hybridization strategy on previously described 1,2-disubstituted-4(1H)-pyridinone derivatives, considered as lead compounds, which present potent analgesic properties (M. D. Aytemir, T. Uzbay, D. D. Erol, Arzneim. Forsch. (Drug Res.) 49 (1999) 250). Their chemical structures have been proved by means of their IR and 1H NMR data and by elemental analysis. The analgesic profile of the title compounds (4-11), evaluated by the model of abdominal constrictions induced by acetic acid, showed that all the 4(1H)-pyridinone derivatives were active, exhibiting an analgesic activity comparable with that of aspirin (acetyl salicylic acid) used as a standard. The antiinflammatory profile by the synthesized compounds, evaluated by the model of carrageenan rat paw edema, showed that all compounds were active and were comparable with indomethacin used as a standard.